Beyond One-Size-Fits-All: The Rise of Personalized Medicine for Oncology

Cancer is one of the leading causes of death globally, with about 1 in 8 people dying of cancer in 2022, as per the World Health Organization. While considerable progress has been made in the fight against cancer, it continues to cause grief and suffering across the world, as more and more people are diagnosed with cancers affecting different tissues and organs. Although significant advances have been made in cancer treatment, these therapies are effective in only a minority of patients.

The major challenge in oncology is that no two cancers are alike, even within the same tissue, complicating treatment responses and relapse rates. Tumor heterogeneity arises from the diversity of cell types within tumors and unique gene mutations in these cells, which influence cancer progression and treatment response. Additionally, the spatial organization of cancer cells and their interactions with neighboring cells shape the tumor microenvironment (TME). This spatial architecture impacts tumor development, metastasis, and drug efficacy, highlighting the complexity of each cancer case.
Source Url

elucidata .io
Author: elucidata .io

Website: https://www.elucidata.io/ Website: https://www.elucidata.io/ Elucidata leverages its platform, Polly to augment the quality of data in pre-clinical drug discovery. It curates multi-omics and assay data to make them ML-ready or analysis-ready. Our exceptional multi-disciplinary team of experts use Polly’s powerful curation engine to harmonize a diverse array of data-types, curate metadata and process data consistently at affordable costs while maintaining information-richness. We are one of the only companies to offer a tech-enabled approach to multi-modal data curation that serves the life science industry. Polly’s technology and experts have helped R&D teams arrive at multiple validated drug targets across immunology, oncology, and metabolomic disorders. Currently, 25+ research organizations, including 4 of the largest 10 pharma companies are using Polly and its allied solutions to accelerate their discovery programs. Many other data-driven healthcare companies also use Polly to process, harmonize and store public or in-house biomedical data. Address: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Phone No: 9716140329 Contact Email: info@elucidata.io

elucidata .io

Website: https://www.elucidata.io/ Website: https://www.elucidata.io/ Elucidata leverages its platform, Polly to augment the quality of data in pre-clinical drug discovery. It curates multi-omics and assay data to make them ML-ready or analysis-ready. Our exceptional multi-disciplinary team of experts use Polly’s powerful curation engine to harmonize a diverse array of data-types, curate metadata and process data consistently at affordable costs while maintaining information-richness. We are one of the only companies to offer a tech-enabled approach to multi-modal data curation that serves the life science industry. Polly’s technology and experts have helped R&D teams arrive at multiple validated drug targets across immunology, oncology, and metabolomic disorders. Currently, 25+ research organizations, including 4 of the largest 10 pharma companies are using Polly and its allied solutions to accelerate their discovery programs. Many other data-driven healthcare companies also use Polly to process, harmonize and store public or in-house biomedical data. Address: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Phone No: 9716140329 Contact Email: info@elucidata.io